Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

被引:18
作者
Zhang, Luping [1 ]
Xu, Yanmei [2 ]
Shen, Jie [1 ]
He, Feng [1 ]
Zhang, Dan [1 ]
Chen, Zhengtang [1 ]
Duan, Yuzhong [1 ]
Sun, Jianguo [1 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Inst Canc, PLA, Chongqing 400037, Peoples R China
[2] Leshan Peoples Hosp, Dept Oncol, Leshan 614000, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Dendritic cells; cytokine-induced killer cells; thoracic radiotherapy; non-small cell lung cancer; cytotherapy; INDUCED KILLER-CELLS; DENDRITIC CELLS; TUMOR-CELLS; T-CELLS; IMMUNOTHERAPY; COMBINATION; RADIATION; MELANOMA; CHEMOTHERAPY; IRRADIATION;
D O I
10.1186/s13014-016-0635-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The combination of dendritic cells (DCs) and cytokine-induced killer cells (CIKs) can induce the anti-tumor immune response and radiotherapy may promote the activity. We aimed to explore the feasibility of DCs/CIKs combined with thoracic radiotherapy (TRT) for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). Method: In this study, patients with unresectable stage III/IV NSCLC and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2 and previously receiving two or more cycles of platinum-based doublet chemotherapy without disease progression received TRT plus DCs/CIKs or TRT alone until disease progression or unacceptable toxicity. The primary endpoint was median progression-free survival (mPFS). In treatment group, patients received four-cycle autologous DCs/CIKs infusion starting from the 6th fraction of irradiation. Results: From Jan 13, 2012 to June 30, 2014, 82 patients were enrolled, with 21 patients in treatment group and 61 in control group. The mPFS in treatment group was longer than that in control group (330 days vs 233 days, hazard ratio 0.51, 95 % CI 0.27-1.0, P < 0.05), and the objective response rate (ORR) of treatment group (47.6 %) was significantly higher that of control group (24.6 %, P < 0.05). There was no significant difference in disease control rate (DCR) and median overall survival (mOS) between two groups (P > 0.05). The side effects in treatment group were mild and there was no treatment-related deaths. Conclusion: The combination of DCs/CIKs with TRT could be a feasible regimen in treating locally advanced or metastatic NSCLC patients. Further investigation of the regimen is warranted.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
    Allemani, Claudia
    Weir, Hannah K.
    Carreira, Helena
    Harewood, Rhea
    Spika, Devon
    Wang, Xiao-Si
    Bannon, Finian
    Ahn, Jane V.
    Johnson, Christopher J.
    Bonaventure, Audrey
    Marcos-Gragera, Rafael
    Stiller, Charles
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Ogunbiyi, Olufemi J.
    Rachet, Bernard
    Soeberg, Matthew J.
    You, Hui
    Matsuda, Tomohiro
    Bielska-Lasota, Magdalena
    Storm, Hans
    Tucker, Thomas C.
    Coleman, Michel P.
    [J]. LANCET, 2015, 385 (9972) : 977 - 1010
  • [2] [Anonymous], 2010, GEN RUL CLIN PATH RE
  • [3] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [4] Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
    Brodowicz, T
    Krzakowski, M
    Zwitter, M
    Tzekova, V
    Ramlau, R
    Ghilezan, N
    Ciuleanuf, T
    Cucevic, B
    Gyurkovits, K
    Ulsperger, E
    Jassem, J
    Grgic, M
    Pinar, S
    Szilasi, M
    Wiltschke, C
    Wagnerova, M
    Oskina, N
    Soldatenkova, V
    Zielinski, C
    Wenczl, M
    [J]. LUNG CANCER, 2006, 52 (02) : 155 - 163
  • [5] The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing
    Chakraborty, Mala
    Wansley, Elizabeth K.
    Carrasquillo, Jorge A.
    Yu, Sarah
    Paik, Chang H.
    Camphausen, Kevin
    Becker, Michael D.
    Goeckeler, William F.
    Schlom, Jeffrey
    Hodge, James W.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4241 - 4249
  • [6] Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma
    Chi, KW
    Liu, SD
    Li, CP
    Kuo, HP
    Wang, YS
    Chao, Y
    Hsieh, SL
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) : 129 - 135
  • [7] Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients
    Cui, Yu
    Yang, Xuejing
    Zhu, Wei
    Li, Jiali
    Wu, Xiaojing
    Pang, Yan
    [J]. ONCOLOGY LETTERS, 2013, 6 (02) : 537 - 541
  • [8] Demaria S, 2005, CLIN CANCER RES, V11, P728
  • [9] Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
    Deng, Liufu
    Liang, Hua
    Burnette, Byron
    Beckett, Michael
    Darga, Thomas
    Weichselbaum, Ralph R.
    Fu, Yang-Xin
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) : 687 - 695
  • [10] Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
    Draube, Andreas
    Klein-Gonzalez, Nela
    Mattheus, Stefanie
    Brillant, Corinne
    Hellmich, Martin
    Engert, Andreas
    von Bergwelt-Baildon, Michael
    [J]. PLOS ONE, 2011, 6 (04):